Literature DB >> 31915279

PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor.

Chuan Xia1,2, Jennifer J Wolf2, Chuankai Sun3, Mengqiong Xu3, Caleb J Studstill2, Jun Chen3, Hanh Ngo2, Hua Zhu3,4, Bumsuk Hahm5.   

Abstract

Influenza A virus (IAV) utilizes multiple strategies to confront or evade host type I interferon (IFN)-mediated antiviral responses in order to enhance its own propagation within the host. One such strategy is to induce the degradation of type I IFN receptor 1 (IFNAR1) by utilizing viral hemagglutinin (HA). However, the molecular mechanism behind this process is poorly understood. Here, we report that a cellular protein, poly(ADP-ribose) polymerase 1 (PARP1), plays a critical role in mediating IAV HA-induced degradation of IFNAR1. We identified PARP1 as an interacting partner for IAV HA through mass spectrometry analysis. This interaction was confirmed by coimmunoprecipitation analyses. Furthermore, confocal fluorescence microscopy showed altered localization of endogenous PARP1 upon transient IAV HA expression or during IAV infection. Knockdown or inhibition of PARP1 rescued IFNAR1 levels upon IAV infection or HA expression, exemplifying the importance of PARP1 for IAV-induced reduction of IFNAR1. Notably, PARP1 was crucial for the robust replication of IAV, which was associated with regulation of the type I IFN receptor signaling pathway. These results indicate that PARP1 promotes IAV replication by controlling viral HA-induced degradation of host type I IFN receptor. Altogether, these findings provide novel insight into interactions between influenza virus and the host innate immune response and reveal a new function for PARP1 during influenza virus infection.IMPORTANCE Influenza A virus (IAV) infections cause seasonal and pandemic influenza outbreaks, which pose a devastating global health concern. Despite the availability of antivirals against influenza, new IAV strains continue to persist by overcoming the therapeutics. Therefore, much emphasis in the field is placed on identifying new therapeutic targets that can more effectively control influenza. IAV utilizes several tactics to evade host innate immunity, which include the evasion of antiviral type I interferon (IFN) responses. Degradation of type I IFN receptor (IFNAR) is one known method of subversion, but the molecular mechanism for IFNAR downregulation during IAV infection remains unclear. Here, we have found that a host protein, poly(ADP-ribose) polymerase 1 (PARP1), facilitates IFNAR degradation and accelerates IAV replication. The findings reveal a novel cellular target for the potential development of antivirals against influenza, as well as expand our base of knowledge regarding interactions between influenza and the host innate immunity.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  PARP1; hemagglutinin; influenza A virus; type I interferon receptor

Year:  2020        PMID: 31915279     DOI: 10.1128/JVI.01572-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  10 in total

1.  TRAF3 Positively Regulates Host Innate Immune Resistance to Influenza A Virus Infection.

Authors:  Fangzhao Chen; Liurong Chen; Yinyan Li; Huiting Sang; Chunyu Zhang; Shuofeng Yuan; Jie Yang
Journal:  Front Cell Infect Microbiol       Date:  2022-04-27       Impact factor: 6.073

Review 2.  ADP-ribosylation in evasion, promotion and exacerbation of immune responses.

Authors:  Maria Manuela Rosado; Claudio Pioli
Journal:  Immunology       Date:  2021-04-12       Impact factor: 7.215

3.  PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.

Authors:  Valentina Perini; Michelle Schacke; Pablo Liddle; Salomé Vilchez-Larrea; Deborah J Keszenman; Laura Lafon-Hughes
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

4.  IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages.

Authors:  Brent A Stanfield; Todd Purves; Scott Palmer; Bruce Sullenger; Karen Welty-Wolf; Krista Haines; Suresh Agarwal; George Kasotakis
Journal:  PLoS One       Date:  2021-01-20       Impact factor: 3.240

5.  An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.

Authors:  Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Xiaoting Wang; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Yunan Luo; Lili Cheng; Chengliang Hu; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Yunfu Wu; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Ligong Chen; Haitao Li; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng
Journal:  Signal Transduct Target Ther       Date:  2021-04-24

Review 6.  NAD+-consuming enzymes in immune defense against viral infection.

Authors:  Jialin Shang; Michael R Smith; Ananya Anmangandla; Hening Lin
Journal:  Biochem J       Date:  2021-12-10       Impact factor: 3.857

Review 7.  Virus-Host Interplay Between Poly (ADP-Ribose) Polymerase 1 and Oncogenic Gammaherpesviruses.

Authors:  Woo-Chang Chung; Moon Jung Song
Journal:  Front Microbiol       Date:  2022-01-14       Impact factor: 5.640

8.  Enzymatic independent role of sphingosine kinase 2 in regulating the expression of type I interferon during influenza A virus infection.

Authors:  Mengqiong Xu; Sisi Xia; Mei Wang; Xiaolian Liu; Xin Li; Weijie Chen; Yaohao Wang; Hongjian Li; Chuan Xia; Jun Chen; Jianguo Wu
Journal:  PLoS Pathog       Date:  2022-09-07       Impact factor: 7.464

Review 9.  Host-Virus Interaction: How Host Cells Defend against Influenza A Virus Infection.

Authors:  Yun Zhang; Zhichao Xu; Yongchang Cao
Journal:  Viruses       Date:  2020-03-29       Impact factor: 5.048

Review 10.  The Antiviral Activities of Poly-ADP-Ribose Polymerases.

Authors:  Mathilde Malgras; Magali Garcia; Clément Jousselin; Charles Bodet; Nicolas Lévêque
Journal:  Viruses       Date:  2021-03-30       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.